1023 related articles for article (PubMed ID: 29473376)
1. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
2. Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
Vanneste M; van der Heij B; Christiaansen CE; Berendsen CL; Driessen EJM; Bruins HM
World J Urol; 2023 Aug; 41(8):2173-2178. PubMed ID: 37328699
[TBL] [Abstract][Full Text] [Related]
3. Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy.
McFadden J; Tachibana I; Adra N; Collins K; Cary C; Koch M; Kaimakliotis H; Masterson TA; Rice KR
Urol Oncol; 2024 Mar; 42(3):69.e11-69.e16. PubMed ID: 38267301
[TBL] [Abstract][Full Text] [Related]
4. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success.
Lebret T; Gaudez F; Hervé JM; Barré P; Lugagne PM; Botto H
Eur Urol; 1998; 34(1):67-72. PubMed ID: 9676417
[TBL] [Abstract][Full Text] [Related]
5. Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era.
Yanagisawa T; Kawada T; von Deimling M; Bekku K; Laukhtina E; Rajwa P; Chlosta M; Pradere B; D'Andrea D; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
Eur Urol Focus; 2024 Jan; 10(1):41-56. PubMed ID: 37495458
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes.
Li H; Wang L; Li H; Zhang P; Li Z; Xue L; Wang Z; Fu D; Chen Q; Luo Q; Chong T; Wang Z
Oncology; 2024; 102(4):337-342. PubMed ID: 37647883
[TBL] [Abstract][Full Text] [Related]
7. Efficiency of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer: An umbrella review.
Li DX; Yu QX; Wu RC; Wang J; Feng DC; Deng S
Cancer Med; 2024 Jun; 13(11):e7323. PubMed ID: 38819629
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of 34 cases of infiltrating carcinoma of the bladder treated exclusively with partial cystectomy (part 1)].
Escudero Barrilero A; Fernández Fernández E; Jiménez Cidre M; Maganto Pavón E; Mayayo Dehesa T; Rodríguez Rodríguez R; Galvis San Juan F; Burgos Revilla FJ
Arch Esp Urol; 1996 May; 49(4):349-64. PubMed ID: 8754191
[TBL] [Abstract][Full Text] [Related]
9. The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder.
Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Hsu TH; Chang LS
Br J Urol; 1996 Aug; 78(2):209-12. PubMed ID: 8813915
[TBL] [Abstract][Full Text] [Related]
10. Invasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection. A survival analysis focusing on TUR as monotherapy.
Roosen JU; Geertsen U; Jahn H; Weinreich J; Nissen HM
Scand J Urol Nephrol; 1997 Feb; 31(1):39-42. PubMed ID: 9060082
[TBL] [Abstract][Full Text] [Related]
11. Safety, feasibility, and quality of thulium laser en-bloc resection for treatment of non-muscle invasive bladder cancer.
Assem A; Kassem A; Sherif M; Lotfi A; Abdelwahed M
Int Urol Nephrol; 2023 Dec; 55(12):3103-3109. PubMed ID: 37639155
[TBL] [Abstract][Full Text] [Related]
12. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up.
Malmström PU; Busch C; Norlén BJ
Scand J Urol Nephrol; 1987; 21(3):185-95. PubMed ID: 3433019
[TBL] [Abstract][Full Text] [Related]
13. pT1 Subclassification Predicts Progression-Free Survival in En Bloc Resection of Bladder Tumor Specimens.
Sato S; Yanagisawa T; Miki J; Hayashida Y; Okada Y; Iwatani K; Matsukawa A; Kimura T; Egawa S; Shimoda M; Takahashi H
Arch Pathol Lab Med; 2024 May; 148(5):573-580. PubMed ID: 37671794
[TBL] [Abstract][Full Text] [Related]
14. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
Contieri R; Tan WS; Grajales V; Hensley PJ; Martini A; Bree K; Myers A; Nogueras-Gonzalez G; Navai N; Dinney CP; Guo C; Kamat AM
BJU Int; 2024 Jun; 133(6):733-741. PubMed ID: 38374533
[TBL] [Abstract][Full Text] [Related]
15. Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
Matsushita Y; Miyake M; Nishimura N; Nishimoto K; Fukuhara H; Kobayashi K; Oyama M; Inoue K; Matsuyama H; Fujimoto K; Miyake H
Int J Clin Oncol; 2024 Feb; 29(2):205-212. PubMed ID: 38112832
[TBL] [Abstract][Full Text] [Related]
16. Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.
Arnaud Q; Sebe P; Colau A; Mouton M; Desgrandchamps F; Masson-Lecomte A; Bessede T; Irani J; Dominique I
Fr J Urol; 2024 Jan; 34(1):102548. PubMed ID: 37980231
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in superficial bladder cancer.
Ozen HA; Akdaş A; Alkibay T; Altuğ U; Remzi D
Int Urol Nephrol; 1986; 18(4):417-20. PubMed ID: 3818217
[TBL] [Abstract][Full Text] [Related]
18. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study.
Soria F; Rosazza M; Livoti S; Dutto D; Colucci F; Sylvester RJ; Shariat SF; Babjuk M; Palou J; Gontero P
Eur Urol Focus; 2023 Nov; ():. PubMed ID: 37923633
[TBL] [Abstract][Full Text] [Related]
19. Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer.
Bono AV; Benvenuti C; Damiano G; Lovisolo J
Urology; 1994 Sep; 44(3):329-34; discussion 334-5. PubMed ID: 8073548
[TBL] [Abstract][Full Text] [Related]
20. Bladder tumors invading the lamina propria (stage A/T1): influence of endovesical bacillus Calmette-Guérin therapy on recurrence and progression.
Boccon-Gibod L; Leleu C; Herve JM; Belas M; Steg A
Eur Urol; 1989; 16(6):401-4. PubMed ID: 2591423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
